Company Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
The company’s lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection.
In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas.
The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019.
Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Marc Hedrick |
Contact Details
Address: 6420 LEVIT GREEN BOULEVARD, SUITE 210 Houston, Texas 77021 United States | |
| Phone | 737 255 7194 |
| Website | plustherapeutics.com |
Stock Details
| Ticker Symbol | PSTV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1095981 |
| CUSIP Number | 72941H400 |
| ISIN Number | US72941H5090 |
| Employer ID | 33-0827593 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marc H. Hedrick M.B.A., M.D. | President, Chief Executive Officer and Director |
| Andrew J. Sims CPA | Vice President and Chief Financial Officer |
| Russ Havranek M.B.A., M.S. | Executive Vice President of Commercial and Corporate Strategy |
| Desiree Smith | Corporate Controller |
| Russell W. Bradley | President and GM of CNSide Diagnostics, LLC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2026 | 8-K | Current Report |
| Mar 31, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2026 | ARS | Filing |
| Mar 31, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 10-K | Annual Report |
| Mar 12, 2026 | 8-K | Current Report |
| Mar 6, 2026 | RW | Filing |
| Feb 13, 2026 | 8-K | Current Report |